These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15635025)

  • 1. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates.
    Giakkoupi P; Tzouvelekis LS; Daikos GL; Miriagou V; Petrikkos G; Legakis NJ; Vatopoulos AC
    J Clin Microbiol; 2005 Jan; 43(1):494-6. PubMed ID: 15635025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.
    Tenover FC; Kalsi RK; Williams PP; Carey RB; Stocker S; Lonsway D; Rasheed JK; Biddle JW; McGowan JE; Hanna B
    Emerg Infect Dis; 2006 Aug; 12(8):1209-13. PubMed ID: 16965699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of extended-spectrum beta-lactamase in clinical isolates of Klebsiella pneumoniae in a University Hospital, Thailand.
    Kusum M; Wongwanich S; Dhiraputra C; Pongpech P; Naenna P
    J Med Assoc Thai; 2004 Sep; 87(9):1029-33. PubMed ID: 15516002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
    Padilla E; Alonso D; Doménech-Sánchez A; Gomez C; Pérez JL; Albertí S; Borrell N
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2258-60. PubMed ID: 16723600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sanfetrinem, the member of trinems--in vitro activity against Klebsiella pneumoniae producing ESBL].
    Wieczorek P; Sacha PT; Leszczyńska K; Jakoniuk P; Zalewska M
    Med Dosw Mikrobiol; 2006; 58(1):27-32. PubMed ID: 16871970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
    Vading M; Samuelsen Ø; Haldorsen B; Sundsfjord AS; Giske CG
    Clin Microbiol Infect; 2011 May; 17(5):668-74. PubMed ID: 20649801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
    Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
    J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1.
    Loli A; Tzouvelekis LS; Tzelepi E; Carattoli A; Vatopoulos AC; Tassios PT; Miriagou V
    J Antimicrob Chemother; 2006 Sep; 58(3):669-72. PubMed ID: 16870645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection.
    Bratu S; Mooty M; Nichani S; Landman D; Gullans C; Pettinato B; Karumudi U; Tolaney P; Quale J
    Antimicrob Agents Chemother; 2005 Jul; 49(7):3018-20. PubMed ID: 15980389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates.
    Kim SY; Park YJ; Yu JK; Kim HS; Park YS; Yoon JB; Yoo JY; Lee K
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):85-91. PubMed ID: 16854555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence in Japan of an imipenem-susceptible, meropenem-resistant Klebsiella pneumoniae carrying blaIMP-6.
    Shigemoto N; Kuwahara R; Kayama S; Shimizu W; Onodera M; Yokozaki M; Hisatsune J; Kato F; Ohge H; Sugai M
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):109-12. PubMed ID: 22078906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2).
    Juretschko S; Labombardi VJ; Lerner SA; Schreckenberger PC;
    J Clin Microbiol; 2007 Apr; 45(4):1339-42. PubMed ID: 17229867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
    Kiffer CR; Kuti JL; Eagye KJ; Mendes C; Nicolau DP
    Int J Antimicrob Agents; 2006 Oct; 28(4):340-4. PubMed ID: 16930951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of 500 gram negative isolates to determine the number of major susceptibility interpretation discrepancies between the Vitek and MicroScan Walkaway for 9 antimicrobial agents.
    Rittenhouse SF; Miller LA; Utrup LJ; Poupard JA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):1-6. PubMed ID: 8950521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of antimicrobial susceptibility of bacteria containing the qnr gene and FOX-5 beta-lactamase by four automated systems.
    Rodríguez-Martinez JM; Conejo MC; Martínez-Martínez L; Cano ME; Velasco C; Pascual A
    Clin Microbiol Infect; 2005 May; 11(5):402-4. PubMed ID: 15819868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ongoing challenge of acquired carbapenemases: a hospital outbreak of Klebsiella pneumoniae simultaneously producing VIM-1 and KPC-2.
    Zioga A; Miriagou V; Tzelepi E; Douzinas E; Tsakiri M; Legakis NJ; Daikos GL; Tzouvelekis LS
    Int J Antimicrob Agents; 2010 Aug; 36(2):190-1. PubMed ID: 20510588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.